1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
166.95 USD   +3.15%
06/30BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Form 8-K
PU
06/30BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/30BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3 Trial
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Leerink Cuts BeiGene to Market Perform From Outperform, Price Target to $177 From $300

03/17/2022 | 05:39am EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
06/30BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis..
PU
06/30BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/30BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3..
MT
06/30BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
BU
06/30BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
CI
06/27BeiGene Grants Share Options, Restricted Share Units
MT
06/26Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd...
CI
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/22BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for ..
PU
06/22INSIDER SELL : Beigene
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 426 M - -
Net income 2022 -1 421 M - -
Net cash 2022 2 911 M - -
P/E ratio 2022 -11,2x
Yield 2022 -
Capitalization 17 253 M 17 253 M -
EV / Sales 2022 10,1x
EV / Sales 2023 7,40x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 166,95 $
Average target price 308,10 $
Spread / Average Target 84,5%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-38.38%17 253
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-13.31%44 566
BIONTECH SE-38.91%38 276